The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Hans-Peter Hartung


Moorenstraße 5





Name/email consistency: high



  • Heinrich-Heine-Universität, Moorenstraße 5, Düsseldorf, 40225, Germany. 2012
  • Department of Neurology, Heinrich-Heine-University Medical School, Düsseldorf, Germany. 2002 - 2011


  1. Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies. Hartung, H.P., Kieseier, B., Goodin, D.S., Arnason, B.G., Comi, G., Cook, S., Filippi, M., Jeffery, D.R., Kappos, L., Bogumil, T., Stemper, B., Sandbrink, R., Nakada, Y., Nakajima, H., Schwenke, S., Lehr, S., Heubach, J., Pohl, C., Reischl, J. J. Neuroinflammation (2012) [Pubmed]
  2. Principles of a new treatment algorithm in multiple sclerosis. Hartung, H.P., Montalban, X., Sorensen, P.S., Vermersch, P., Olsson, T. Expert. Rev. Neurother (2011) [Pubmed]
  3. Development of oral cladribine for the treatment of multiple sclerosis. Hartung, H.P., Aktas, O., Kieseier, B., Giancarlo Comi, G.C. J. Neurol. (2010) [Pubmed]
  4. High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis. Hartung, H.P. Expert. Opin. Pharmacother (2009) [Pubmed]
  5. Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology. Hartung, H.P., Mouthon, L., Ahmed, R., Jordan, S., Laupland, K.B., Jolles, S. Clin. Exp. Immunol. (2009) [Pubmed]
  6. Advances in the understanding of the mechanism of action of IVIg. Hartung, H.P. J. Neurol. (2008) [Pubmed]
  7. Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. Hartung, H.P., Polman, C., Bertolotto, A., Deisenhammer, F., Giovannoni, G., Havrdova, E., Hemmer, B., Hillert, J., Kappos, L., Kieseier, B., Killestein, J., Malcus, C., Comabella, M., Pachner, A., Schellekens, H., Sellebjerg, F., Selmaj, K., Sorensen, P.S. J. Neurol. (2007) [Pubmed]
  8. Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference. Hartung, H.P., Munschauer, F., Schellekens, H. Eur. J. Neurol. (2005) [Pubmed]
  9. Early treatment and dose optimisation BENEFIT and BEYOND. Hartung, H.P. J. Neurol. (2005) [Pubmed]
  10. Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis. Hartung, H.P., Kieseier, B.C., Hemmer, B. J. Neurol. (2005) [Pubmed]
  11. Assessment and management of neutralizing antibodies in patients with multiple sclerosis. Hartung, H.P., Munschauer, F.E. J. Neurol. (2004) [Pubmed]
  12. What do we know about the mechanism of action of disease-modifying treatments in MS?. Hartung, H.P., Bar-Or, A., Zoukos, Y. J. Neurol. (2004) [Pubmed]
  13. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Hartung, H.P., Gonsette, R., König, N., Kwiecinski, H., Guseo, A., Morrissey, S.P., Krapf, H., Zwingers, T. Lancet (2002) [Pubmed]
WikiGenes - Universities